EUVIMEDEUVIMED entdecken
Crossref

Construction of [ 89 Zr]Zr-Labeled HuL13 for ImmunoPET Imaging of LAG-3 Checkpoint Expression on Tumor-Infiltrating T Cells

Lixin Ding, Feng Wang, Zilei Wang, Yongxiang Pan, Teli Liu, Liansheng Cheng, Wenting Liu, Kuke Ding, Hua Zhu iD, Zhi Yang iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.4c00343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Lixin Ding und 9 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Resea…. Hauptthemen laut MEDLINE: Lymphocyte Activation Gene 3 Protein, Zirconium, Lymphocytes, Tumor-Infiltrating, Positron-Emission Tomography. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Beijing Municipal Health Commission, Organization Department of the Central Committee of the Communist Party of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lymphocyte activation gene 3 (LAG-3) has attracted much attention as a potentially valuable immune checkpoint. Individual identification of LAG-3 expression at screening and during treatment could improve the successful implementation of anti-LAG-3 therapies. HuL13 is a human IgG1 monoclonal antibody that binds to the LAG-3 receptor in T cells. Here, we used [89Zr]Zr-labeled HuL13 to delineate LAG-3+ T-cell infiltration into tumors via positron emission tomography (PET) imaging. A549/LAG-3 cells, which stably express LAG-3, were generated by infection with lentivirus. The uptake of [89Zr]Zr-DFO-HuL13 in A549/LAG-3 cells was greater than that in the negative control (A549/NC) cells at each time point. The equilibrium dissociation constant (Kd) of [89Zr]Zr-DFO-HuL13 for the LAG-3 receptor was 8.22 nM. PET imaging revealed significant uptake in the tumor areas of A549/LAG-3 tumor-bearing mice from 24 h after injection (SUVmax = 2.43 ± 0.06 at 24 h). As a proof of concept, PET imaging of the [89Zr]Zr-DFO-HuL13 tracer was further investigated in an MC38 tumor-bearing humanized LAG-3 mouse model. PET imaging revealed that the [89Zr]Zr-DFO-HuL13 tracer specifically targets human LAG-3 expressed on tumor-infiltrating lymphocytes (TILs). In addition to the tumors, the spleen was also noticeably visible. Tumor uptake of the [89Zr]Zr-DFO-HuL13 tracer was lower than its uptake in the spleen, but high uptake in the spleen could be reduced by coinjection of unlabeled antibodies. Coinjection of unlabeled antibodies increases tracer activity in the blood pool, thereby improving tumor uptake. Dosimetry evaluation of the healthy mouse models revealed that the highest absorbed radiation dose was in the spleen, followed by the liver and heart wall. In summary, these studies demonstrate the feasibility of using the [89Zr]Zr-DFO-HuL13 tracer for the detection of LAG-3 expression on TILs. Further clinical evaluation of the [89Zr]Zr-DFO-HuL13 tracer may be of significant help in the stratification and management of patients suitable for anti-LAG-3 therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocyte Activation Gene 3 ProteinZirconiumLymphocytes, Tumor-InfiltratingPositron-Emission TomographyAnimalsHumansMiceCell Line, TumorAntigens, CDRadioisotopesAntibodies, MonoclonalFemaleTissue Distribution

Stichwörter der Autor:innen

LAG-3immune checkpointimmunoPETtumor-infiltrating lymphocyteszirconium-89

Substanzen

Lymphocyte Activation Gene 3 ProteinZirconiumZirconium-89Antigens, CDRadioisotopesLag3 protein, humanAntibodies, Monoclonal

Autor:innen und Institutionen

  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceu…
  • Hefei HankeMab Biotechnology Limited, Hefei, Anhui 230088, China.
  • Office for Public Health Management, Chinese Center for Disease Control and Prevention, Beijing 102206, China.

ORCID-Profile: Hua Zhu, Zhi Yang

Förderung

  • Beijing Municipal Health Commission
  • Organization Department of the Central Committee of the Communist Party of China
  • National Natural Science Foundation of China

Zitieren

APA

Ding, L., Wang, F., Wang, Z., Pan, Y., Liu, T., Cheng, L., Liu, W., Ding, K., Zhu, H., & Yang, Z. (2024). Construction of [ 89 Zr]Zr-Labeled HuL13 for ImmunoPET Imaging of LAG-3 Checkpoint Expression on Tumor-Infiltrating T Cells. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.4c00343

Vancouver

Ding L, Wang F, Wang Z, Pan Y, Liu T, Cheng L, et al. Construction of [ 89 Zr]Zr-Labeled HuL13 for ImmunoPET Imaging of LAG-3 Checkpoint Expression on Tumor-Infiltrating T Cells. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.4c00343

BibTeX
@article{Ding2024,
  author = {Ding, Lixin and Wang, Feng and Wang, Zilei and Pan, Yongxiang and Liu, Teli and Cheng, Liansheng and Liu, Wenting and Ding, Kuke and Zhu, Hua and Yang, Zhi},
  title = {Construction of [ 89 Zr]Zr-Labeled HuL13 for ImmunoPET Imaging of LAG-3 Checkpoint Expression on Tumor-Infiltrating T Cells},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.4c00343}
}
Kostenlos starten →